INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,627,000 | -17.7% | 300,000 | 0.0% | 2.20% | -21.2% |
| Q2 2023 | $18,996,000 | +16.9% | 300,000 | 0.0% | 2.80% | +15.5% |
| Q1 2023 | $16,245,000 | +27.9% | 300,000 | +25.0% | 2.42% | +31.2% |
| Q4 2022 | $12,700,800 | -57.3% | 240,000 | -62.5% | 1.84% | -49.5% |
| Q3 2022 | $29,779,000 | -25.5% | 640,000 | -8.6% | 3.65% | -39.8% |
| Q2 2022 | $39,956,000 | -6.7% | 700,000 | 0.0% | 6.06% | -29.2% |
| Q1 2022 | $42,833,000 | +6624.2% | 700,000 | +1589.0% | 8.57% | +9528.1% |
| Q1 2020 | $637,000 | – | 41,444 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |